Paratek Pharmaceuticals (PRTK) announced positive results from Phase 3 registration study comparing its once-daily, broad spectrum antibiotic, omadacycline, to linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The firm’s press release stated that its antibiotic drug met the FDA-specified primary efficacy endpoint of early clinical response.

The study has also met the European Medicines Agency (EMA)-specified co-primary efficacy endpoints for post-treatment evaluation.

The positive results came from the first of two Phase 3 registration studies designed . . .